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Abstract
West Nile fever (WNF) has been assessed according to the criteria of the Animal Health Law (AHL), in
particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of WNF to be
listed, Article 9 for the categorisation of WNF according to disease prevention and control rules as in
Annex IV and Article 8 on the list of animal species related to WNF. The assessment has been
performed following a methodology composed of information collection and compilation, expert
judgement on each criterion at individual and, if no consensus was reached before, also at collective
level. The output is composed of the categorical answer, and for the questions where no consensus
was reached, the different supporting views are reported. Details on the methodology used for this
assessment are explained in a separate opinion. According to the assessment performed, WNF can be
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL. The
disease would comply with the criteria as in Sections 2 and 5 of Annex IV of the AHL, for the
application of the disease prevention and control rules referred to in points (b) and (e) of Article 9(1).
The animal species to be listed for WNF according to Article 8(3) criteria are several orders of birds
and mammals as susceptible species and several families of birds as reservoir. Different mosquito
species can serve as vectors.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017a).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017a).
The present document reports the results of assessment on West Nile fever (WNF) according to the
criteria of the AHL articles as follows:
• Article 7: West Nile fever proﬁle and impacts
• Article 5: eligibility of West Nile fever to be listed
• Article 9: categorisation of West Nile fever according to disease prevention and control rules as
in Annex IV
• Article 8: list of animal species related to West Nile fever.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017a).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of WNF according to the Article 7 criteria of the AHL and
related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017a)), based on
the information contained in the fact sheet as drafted by the selected disease scientist (see Section 2.1
of the scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
West Nile virus (WNV) belongs to the Flaviviridae family, genus Flavivirus, and is included in the
serocomplex of Japanese Encephalitis virus together with Murray Valley encephalitis (MVE), St. Louis
encephalitis (SLE), Kunjin (KUN), Usutu (USU), Koutango (KOU), Cacipacore (CPC), Alfuy (ALF) and
Yaounde (YAO) viruses. Apart from Usutu virus, the other viruses in the serocomplex are not present
in Europe. The virus was isolated for the ﬁrst time in 1937 in Uganda, from the blood of a woman with
febrile symptoms who came from the West Nile district (hence the name West Nile fever).
Different genetic lineages have been identiﬁed worldwide but the strains responsible for serious
epidemics are attributable to Lineage 1 and, more recently, also to Lineage 2. Phylogenetic analyses
revealed that all European WNV lineage 1 and 2 strains are derived from a limited number of
independent introductions, most likely from Africa, followed by local spread and evolution. Other
lineages have been identiﬁed but not associated so far with human or animal diseases.
WNV is transmitted by different genera and species of mosquitoes. The main vectors are some of
the species of ornithophilic mosquitoes belonging to the genus Culex, which is always closely
associated with the transmission of WNV during outbreaks. The mosquitoes cease their activity during
the colder months, but it has been demonstrated that the virus is able to survive during this period in
the infected mosquitoes, which overwinter indoors.
AHL assessment on West Nile fever
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3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
Several orders of birds can be naturally susceptible to WNV infections, i.e. Anseriformes, Apodiformes,
Caprimulgiformes, Casuariiformes, Charadriiformes, Ciconiformes, Columbiformes, Coraciiformes, Cuculi-
formes, Falconiformes, Galliformes, Gaviformes, Gruiformes, Musophagiformes, Passeriformes, Pelecani-
formes, Piciformes, Podicipediformes, Psittaciformes, Spheniscformes, Strigiformes and Struthioniformes.
Also several orders of mammals can be naturally susceptible to WNV infections, i.e. Artiodactyla,
Carnivora, Chiroptera, Perissodactyla, Primates, Proboscidea and Rodentia.
Two orders of reptiles can be naturally susceptible to WNV infections: Crocodylia and Squamata.
Details concerning the susceptible families and species of the above mentioned orders are listed in
Table A.1 in Appendix A.
Parameter 2 – Naturally susceptible domestic species (or family/orders)
Several families of domestic animals can be naturally susceptible to WNV infections, i.e.
Phasianidae, Anatidae, Bovidae, Canidae, Felidae, Leporidae and Equidae.
Details concerning the susceptible species of the above mentioned families are listed in Table A.2 in
Appendix A.
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
Several wild birds of the orders Passeriformes, Falconiformes, Accipitriformes, Strigiformes,
Galliformes, Pelecaniformes, Columbiformes, Gruiformes, Anseriformes, Charadriiformes, Psittaciformes
and Piciformes were successfully infected (see Table A.3 in Appendix A for the outcomes of
experimental infections of WNV performed in wild birds (adapted from Perez-Ramırez et al. (2014)
(Perez-Ramırez et al., 2014)).
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
Table A.4 in Appendix A lists the outcomes of experimental infections of WNV performed in
domestic animal species. Infections have been successfully established in cats, dogs, horses, pigs,
rabbits and sheep.
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
Several bird species, particularly passerine species (jays, ﬁnches, sparrows, and crows) can be
potential reservoirs of WNV. House ﬁnches (Carpodacus mexicanus) and house sparrows
(Passer domesticus) experimentally inoculated showed persistent infection in spleen and kidney
28 weeks p.i. (post infection). The virus was still detected by real time reverse transcription
polymerase chain reaction (RT-PCR) in the spleen of two house sparrows at 36 weeks p.i. However,
viral isolation attempts were unsuccessful (Wheeler et al., 2012). In a previous work (Nemeth et al.,
2009a), a higher number of organs were analysed in WNV-infected house sparrows, and viral RNA was
detected in juvenile sparrows up to 65 days p.i in kidney and spleen, although infectious virus could be
isolated at low titres only in one sparrow at 43 days p.i. Reisen et al. (2006) conﬁrmed the persistent
infection in ﬁve species of Passeriformes and in common ground-dove (Columbina passerina) detecting
the virus in spleen and kidney, but also in lungs at > 6 weeks p.i. (Reisen et al., 2006).
Outside the United States of America (USA), clinical symptoms signs due to WNV infection have
been reported in few cases and limited to scarce number of avian species in course of outbreaks:
domestic geese (Anser anser domesticus) and white storks (Ciconia ciconia) during the WNV epidemic
in Israel (Malkinson et al., 2002), goshawks (Accipiter gentilis) in Hungary (Bakonyi et al., 2006),
Eurasian jays (Garrulus glandarius), little owl (Athene noctua), mallard (Anas plathyrynchos), and
common buzzard (Buteo buteo) in Italy (Monaco et al., 2015). However, mass mortality of highly
susceptible species (such as corvids or other species) is less frequently observed in the Old than in the
New World although some species, as the jackdaws (Corvus monedula) could potentially function as
sentinel (Lim et al., 2014). Surveillance activities carried out in Italy where WNV is endemic since 2008,
pointed out the high susceptibility to the viral infection of three species of synantropic resident wild
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birds, namely carrion crow (Corvus corone), magpie (Pica pica) and Eurasian jay (Garrulus glandarius)
which justiﬁes their use as sentinel in endemic areas (Italian Ministry of Health, 2016).
Some species of mammals including squirrels (Sciurus sp.), eastern chipmunks (Tamias striatus)
and eastern cottontail rabbits (Sylvilagus ﬂoridanus) may be capable of transmitting WNV to
mosquitoes, although their epidemiological role importance as reservoir hosts is still uncertain.
Among reptiles, clinical signs were mainly reported during outbreaks in alligators, although there is
also a report on neurological signs associated with WNV infection in a crocodile monitor
(Varanus salvadori) lizard. Some infections in garter snakes (Thamnophis sirtalis) experimentally
inoculated with WNV were also fatal. Green iguanas (Iguana iguana) can be infected.
Amphibians including lake frogs (Rana ridibunda) and North American bullfrogs (Rana catesbeiana)
can also be infected with WNV. Some alligators (e.g. American alligators, Alligator mississippiensis) and
frogs (e.g. Rana ridibunda in Russia) may develop viraemia sufﬁcient to infect mosquitoes. As with
mammals, their epidemiological importance as reservoir hosts is still uncertain.
Based on preliminary research carried out in Italy and Spain, only a few bird species seem to play a
major role in the transmission of infection to the mosquitoes (Hamer et al., 2009; Munoz et al., 2012;
Roiz et al., 2012; Spedicato et al., 2016). Unfortunately, the reservoir competence for many European
bird species is still unknown even though the persistence of WNV in infected birds has been assessed
in some species through experimental trials. Table B.1 in Appendix B provides an overview of wild and
domestic WNV reservoir/sentinel animal species.
Parameter 6 – Domestic reservoir species (or family/orders)
WNV has been associated with sporadic disease infection in small numbers of domestic animal
species (see above in parameter 2 and Table A.2 in Appendix A); however, these species do not play a
role in the further transmission of WNV to mosquitoes and are thus considered as dead-end hosts. See
also Table B.1 in Appendix B which lists wild and domestic WNV reservoir/sentinel animal species.
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Parameter 1 – Prevalence/incidence
WNV has been found in all the continents from tropical to north temperate latitudes (Reisen, 2013).
Table 1 lists the number of horses positive for WNV detections (either by immunoglobulin M enzyme-
linked immunosorbent assay (IgM-ELISA) or PCR), reported to the Animal Diseases Notiﬁcation System
since between (ADNS) 2013 and 2016.
Table 1: Number of horses positive for WNV reported to the ADNS
Country Year Number of positive horses
France 2015 386
Italy 2013 341
Italy 2014 284
Italy 2015 339
Italy 2016 707
Greece 2013 575
Greece 2014 55
Spain 2013 330
Spain 2014 158
Spain 2015 309
Spain 2016 909
Portugal 2015 283
Portugal 2016 35
Austria 2016 17
Hungary 2013 12
Hungary 2014 91
Hungary 2015 92
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Table C.1 in Appendix C summarises the prevalence of cases reported to the OIE in Europe, namely
in Portugal, Spain, France, Croatia, Greece, Romania, Former Yugoslav Republic of Macedonia and
Bulgaria. Also, the cases in Italy reported to the Italian authorities are summarised in Table C.1.
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
WNF can cause disease in horses, several species of birds and rarely in other species such as
camels, dogs, cats, sheep, squirrels and alligators (Go et al., 2014; Hubalek et al., 2014). In horses,
the majority of the infections are asymptomatic, but some individuals (about 10%) can develop severe
neurological illness (ataxia, weakness, recumbency and muscle fasciculation). Experimental infections
have shown that the clinical picture of the disease can be quite divergent depending on the species.
High susceptible species (e.g. corvids) can develop an hyperacute phase resulting in death without
exhibiting symptoms, whereas other species (e.g. raptors, owls, Passeriformes) can develop only mild
lesions with low mortality rates or chronic disease (Perez-Ramırez et al., 2014). The case-morbidity
rate in the outbreaks reported to the OIE and the Italian National Authorities are shown in Table C.1 in
Appendix C.
Parameter 3 – Case-fatality rate
The case-fatality rate in the outbreaks in equids reported to the OIE and the Italian National
Authorities are shown in Table C.1 in Appendix C.
LaDeau et al. (2007) demonstrated that the American crow population declined by up to 45% since
WNV arrival in 1999 and only two of the seven species with documented impact recovered to pre-WNV
levels by 2005 (LaDeau et al., 2007).
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
WNV zoonotic transmission is known to be present in Europe for many years: in the 1960s, the
virus emerged in southern France in the Camargue. Yet, the ﬁrst large outbreak in humans was
reported from Bucharest, Romania in 1996–1997. Up to 2010, infection in humans and/or horses have
been reported in the Czech Republic (1997), France (2000, 2003, 2004, 2006), Italy (1998, 2008,
2009), Hungary (2000–2009), Romania (1997–2001, 2003–2009), Spain (2004) and Portugal (2004).
In 2010, a human outbreak was reported in northern Greece, and human cases were reported in
Romania, Hungary, Italy, Spain and in Volgograd (Russian Federation). The number of human cases
notiﬁed in Europe and in the Mediterranean Basin since 2010 is reported in Table 5.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
This is not applicable to WNV since there is no speciﬁc antiviral therapy.
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
Viral titres in blood equal or greater than 105 TCID50/mL have been considered able to infect
competent mosquito species. In relation to viraemia duration, the following results of experimental
infections in European bird species are reported:
Country Year Number of positive horses
Hungary 2016 945
Bulgaria 2015 2
Bosnia and Herzegovina 2013 0
Source: Animal Diseases Notification System (2013–2016).
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Parameter 2 – Presence and duration of latent infection period
Evidence of persistent WNV infection has been demonstrated in experimentally infected monkeys
(Pogodina et al., 1983) and hamsters (Tesh et al., 2005). WNV is also capable of long-term persistence
in human patients, particularly in the presence of chronic clinical symptoms (Murray et al., 2010). The
importance of these persistent infections, however, needs still to be elucidated, as virus titres are low
and these hosts are considered to be dead-end hosts.
Parameter 3 – Presence and duration of the pathogen in healthy carriers
Refer to the data reported in Section 3.1.1.1 parameter 5.
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
WNV is rapidly inactivated in the environment outside hosts. Low temperatures preserve infectivity,
with stability being greatest below 60°C. It is inactivated by heat (50–60°C for at least 30 min),
ultraviolet light, and gamma irradiation (Burke and Monath, 2001). The virus is also susceptible to
disinfectants such as 3–8% formaldehyde, 2% glutaraldehyde, 2–3% hydrogen peroxide, 500–5,000 ppm
available chlorine, alcohol, 1% iodine and phenol iodophors.
Data related to the persistence of the virus in the vectors are provided in Table 3.
Table 2: Duration of infection period in experimentally infected birds
Species
Viraemia
duration
Cloacal and
oropharyngeal
WNV shedding
Inoculum (WNV isolate,
dose and inoculation
route)
Challenge dose Reference
Rock pigeons
(Columbia livia)
2 days
(viraemia)
15 dpi 3 WNV Italian isolates
(L1*)
(IT/2009-IT/2011-IT/2012)
1 mL subcutaneously
106 TCID50/mL Spedicato
et al. (2016)
Red-legged
partridge
(Alectoris rufa)
4 days
(viraemia)
7 dpi 1 WNV Morocco isolate
(Mo/03) (L1)
1 WNV Spanish isolate
(SP/07)(L1) 0.1 mL
subcutaneously
104 PFU/bird Sotelo et al.
(2011b)
House
sparrows
(Passer
domesticus)
3 days
(viraemia)
12 dpi 2 WNV Italian isolates
(IT/2008 and IT/2009)(L1)
1 WNV Spanish isolate
(SP/07)(L1)
1 WNV US isolate (NY99)
(L1) 0.1 mL
subcutaneously
104 PFU/bird Del Amo
et al. (2014)
Gyrfalcons
(Falco
rusticolus)
4–6 days
(viraemia)
21 dpi 1 WNV US isolate (NY99)
(L1) 1WNV Austrian isolate
(Aus/09)(L2*) 1 mL
subcutaneously
Low dose:
500 TCID50/mL
Medium dose:
104 TCID50/mL
High dose:
106 TCID50/mL
Ziegler et al.
(2013)
WNV: West Nile virus; TCID50: tissue culture infective dose, median; PFU: plaque-forming unit.
Table 3: Detailed outcomes of systematic review on survival time of WNV in mosquitoes at different
temperatures (data extracted from (Turell et al., 2002))
Matrix Target Test Temperatures Maximum detection
Mosquito Nucleic acid RT-PCR 4°, 20°, 70°C 14 days
Mosquito Virus Culture 4°, 20°, 70°C 2 days
RT-PCR: reverse transcription polymerase chain reaction.
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3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
WNV is maintained in nature by a primary cycle of transmission mosquito–bird–mosquito (endemic
cycle): adult ornithophilic mosquitoes (vectors) become infected by biting viraemic birds (amplifying
hosts). A secondary cycle (epidemic cycle) is characterised by the involvement in the transmission
cycle of accidental hosts such as horses and humans due to particular ecological conditions. In this
case, arthropod vectors, called bridge vectors, are able to transmit the virus to hosts other than birds,
such as horses and humans. Humans, equids and other mammals are considered to be dead-end
accidental hosts. In these hosts, the virus does not reach a concentration in the bloodstream high
enough to infect vectors, so the transmission cycle is not perpetuated. In Europe, the transmission
cycle of WNV can be restricted to two main ecosystems: the rural (sylvatic) cycle, which occurs near
wet/marshy areas between wild birds and ornithophilic mosquitoes, and the synanthropic/urban cycle,
which arises between synanthropic or domestic birds and mosquitoes which can feed on the blood of
birds and humans.
WNF vectors are mosquitos belonging to the Culex, Aedes and Coquillettidia genera (family
Culicidae) (link to storymap VBD: https://efsa.maps.arcgis.com/apps/MapJournal/index.html?appid=
512a03aa8df84d54a51bcb69d1b62735) (EFSA AHAW Panel, 2017b).
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
Results of experimental trials on WNV transmission routes in wild birds are summarised in Table 4
and Table A.3 in Appendix A.
Mosquito bites are the usual source of WNV for mammals, reptiles and amphibians; however, in
some animals, there is also evidence for transmission by other routes. Carnivorous mammals and
reptiles (e.g. cats and alligators) can be infected by eating contaminated tissues. Direct transmission
during close contact has also been reported in alligators, possibly via faecal shedding of virus.
Chipmunks, squirrels and raccoons can also shed WNV in faeces, oral secretions and/or urine. WNV
has been found in the urine of experimentally infected hamsters, and in very small amounts in the oral
and/or cloacal ﬂuids of experimentally infected North American bullfrogs (Rana catesbeiana) and green
iguanas (Iguana iguana). Transplacental transmission was reported in experimentally infected sheep
and mice, as well as in a horse that was fatally infected with a Lineage 1 virus in Africa, and aborted in
the ﬁnal stage of the disease. The epidemiological signiﬁcance (if any) of mammalian, reptilian and
amphibian hosts in the maintenance or ampliﬁcation of WNV remains to be established.
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
There is no evidence of natural direct transmission between vertebrates and humans. However,
human infections from the exposure of conjunctival membranes (Fonseca et al., 2005) and/or
percutaneous injury to the body ﬂuids or tissues of WNV-infected birds (CDC, 2002) have been
described.
Table 4: Experimental data on WNV transmission in wild birds
Direct Indirect* Horizontal Vertical Species Reference
C Y Y NT American crow (Corvus brachyrhynchos) Komar et al. (2003)
C Y Y NT Blue jay (Cyanocitta cristata) Komar et al. (2003)
C Y Y NT Black-billed magpie (Pica hudsonia) Komar et al. (2003)
C Y Y NT Ring-billed gull (Larus delawarensis) Komar et al. (2003)
C Y Y N Chicken (Gallus gallus domesticus)** Langevin et al. (2001)
C NT Y N Domestic geese (Anser anser domesticus) Swayne et al. (2001)
C NT NT Common goose (Anser anser domesticus) Banet-Noach et al.
(2003)
C NT Y NT Red-legged partridge (Alectoris rufa) Sotelo et al. (2011b)
NT Y NT NT Canada goose (Branta canadensis) Komar et al. (2003)
N Y N NT Mallard (Anas platyrhynchos) Komar et al. (2003)
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Speed of transmission
Transmission rate of WNV infection between vector (mosquito) and avian population has been
expressed through the calculation of the basic reproduction number (R0) by using different
mathematical models. In the EU context, Calistri et al. (2016) developed a transitional mathematical
model to calculate the R0 values for the various part of the Italian territory from May to September,
which resulted in a mean R0 value for the whole Italy varying between 0.4 and 4.8, with values > 1
from the end of May to the beginning of September.
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
WNV introduction and circulation have been demonstrated on multiple occasions in southern
Europe and in the Mediterranean basin since the 1960s when seropositive animals or virus isolates
were discovered in France, Portugal and Cyprus (Filipe and Pinto, 1969; Joubert et al., 1970).
Migratory birds have been associated with the introduction of viral strains from endemic areas (Calistri
et al., 2010); however, the mechanism of virus persistence in animal hosts in Europe leading to
endemicity of the infection is still unknown.
Direct Indirect* Horizontal Vertical Species Reference
O Y Y NT American kestrel (Falco sparverius) Komar et al. (2003)
(C); Nemeth et al.
(2006a) (O)
N Y N NT Northern bobwhite (Colinus virginianus) Komar et al. (2003)
N Y N NT Japanese quail (Coturnix japonicus) Komar et al. (2003)
NT Y NT NT Ring-necked pheasant (Phasianus
colchicus)
Komar et al. (2003)
N Y N NT American coot (Fulica americana) Komar et al. (2003)
NT Y NT NT Killdeer (Charadrius vociferus) Komar et al. (2003)
N Y N NT Mourning dove (Zenaida macroura) Komar et al. (2003)
N Y N NT Rock dove (Columba livia) Komar et al. (2003)
N Y N NT Monk parakeet (Myiopsitta monachus) Komar et al. (2003)
N Y N NT Budgerigar (Melopsittacus undulatus) Komar et al. (2003)
O Y Y NT Great horned owl (Bubo virginianus) Komar et al. (2003)
(C); Nemeth et al.
(2006a) (O)
NT Y NT NT Northern ﬂicker (Colaptes auratus) Komar et al. (2003)
N Y N NT Fish crow (Corvus ossifragus) Komar et al. (2003)
N Y N NT American robin (Turdus migratorius) Komar et al. (2003)
N Y N NT European starling (Sturnus vulgaris) Komar et al. (2003)
NT Y NT NT Red-winged blackbird (Agelaius
phoeniceus)
Komar et al. (2003)
N Y N NT Common grackle (Quiscalus quiscula) Komar et al. (2003)
N Y N NT House ﬁnch (Carpodacus mexicanus) Komar et al. (2003)
N Y N NT House sparrow (Passer domesticus) Komar et al. (2003)
N NT N NT Red-tailed hawk (Buteo jamaicensis) Nemeth et al. (2006a)
N NT N NT Song sparrow (Melopiza melodia) Reisen and Fang
(2007)
O NT Y NT Eastern screech owls (Megascops asio) Nemeth et al. (2006b)
C: Contact transmission; O: oral transmission; N: no evidence of direct transmission; NT: not tested.
*: Mosquitoes-exposed.
**: Only 1 animal in 16 in contact hens.
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In Europe, WNV circulation was mainly detected in the Mediterranean and south-eastern regions,
where notiﬁcations of human and horses cases of WNV infection have increased in the last 5–7 years,
with the involvement of new areas, where the infection was not notiﬁed before, such as Bulgaria and
Greece in 2010, Albania and Former Yugoslav Republic of Macedonia in 2011, and Croatia, Serbia and
Kosovo in 2012. Accordingly, alarming outbreaks were reported in several European countries in 2010;
261 conﬁrmed human cases, including 34 deaths, occurred in Greece, 57 cases and ﬁve deaths
occurred in Romania, and 480 cases and six deaths occurred in Russia (Papa et al., 2010; Onishchenko
et al., 2011; Sirbu et al., 2011).
Sporadic occurrence of the disease has been reported in France since 1962, when it ﬁrst appeared
in Camargue. In the same region, WNV was detected in 2000, 2004 and, after a ten-year period, in
2015 (Bahuon et al., 2016).
In Italy, WNV annual epidemics have been consistently registered since 2008 (Savini et al., 2008)
caused by genetically divergent isolates and, to date, WNV is considered endemic in the north-eastern
regions of the country, in Sardinia and in Sicily (Italian Ministry of Health, 2016).
The geographic distribution of West Nile cases in Europe and in Mediterranean Basin from 2008 to
2016 shown in Figure 1.
Risk of introduction
Data are not provided since the disease is already present in the Union. It should be noted,
however, that a continuous introduction from Africa through migratory birds is suspected.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
Details concerning the different types of diagnostic tools and their accuracy are listed in Table 7 in
Section 3.1.4.1.
Viral nucleic acid and viral antigens can be demonstrated in tissues of infected animals by RT-PCR
and immuno-histochemistry, respectively.
Antibodies can be detected in equine serum by IgM capture ELISA, haemagglutination inhibition
(HI), IgG ELISA, plaque reduction neutralisation (PRN) or virus neutralisation (VN). In some serological
assays, antibody cross-reactions with related ﬂaviviruses, such as St. Louis encephalitis virus, Usutu
virus, Japanese encephalitis virus or tick-borne encephalitis (TBE) virus may be encountered.
According to the OIE, the following tests are suitable methods for conﬁrmation of clinical cases:
Nested RT-PCR, real time RT-PCR and IgM capture ELISA. The PRN and serum neutralisation tests are
Figure 1: Geographic distribution of cases (conﬁrmed and probable) of West Nile fever in Europe and
in Mediterranean Basin (2008–2016) (source Arbozoonet: https://arbozoonet.izs.it/arb
ozoonet (ArboZoonet, online))
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both suitable methods for detecting prevalence of infection, population freedom from infection and
immune status in animals post-vaccination (Table 7).
Equine WNV-speciﬁc IgM antibodies are usually detectable from 7–10 days to 1–2 months post-
infection. Most of horses with WNV encephalitis test positive in the IgM capture ELISA at the time that
clinical signs are ﬁrst observed. WNV neutralising antibodies are detectable in equine serum by
2 weeks post-infection and can persist for more than 1 year.
Several PCR methods are available as commercial kits. In view of the continued evolution and
possible emergence of new WNV strains, it is important that the designs of PCR tests are constantly
monitored and updated when necessary.
Control tools
Parameter 2 – Existence of control tools
In areas where the disease is endemic, horses may be protected from the clinical signs by
vaccination (Table 7). In the infected areas, however, strategies aiming at reducing the circulation of
the virus through the reduction of mosquito density (reduction/treatment of stagnant water, adulticidal
and larvicidal targeted treatments) and of contacts between vectors and receptive hosts (application of
repellent, mosquito netting, etc.) are the bases of any control policy for mosquito-borne diseases.
Among biocidal products, the use of pyrethrin (6%) and piperonyl butoxide (60%) by aerial spray,
indicated that the odds of infection after spraying were around six times higher in the untreated area
than in treated areas, and that the treatments successfully disrupted the WNV transmission cycle
(Carney et al., 2008).
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
Since the beginning of the 2016 transmission season, the presence of WNV has been conﬁrmed in
MSs and neighbouring countries. As of 27 October 2016, 205 human cases of WNF have been
reported in the EU and 261 cases in the neighbouring countries (Austria, Croatia, Cyprus, Egypt,
Hungary, Italy, Israel, Portugal, Romania, Russian Federation, Serbia, Spain and Syrian Arab republic,
Tunisia, Ukraine) (ECDC, 2016).
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
In European outbreaks, WNV has not been associated with any mortality in domestic birds but has
been connected to a few cases in wild birds (see Section 3.1.1.1).
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Transmissibility between animals and humans
Table 5: Number of cases (conﬁrmed and probable) of West Nile fever in Europe and in
Mediterranean Basin (updated to 2 December 2016)
Country Year Species
No. total
cases(a)
No. conﬁrmed
cases(b)
Source
Albania 2011 Human 2 ECDC (online)
Algeria 2012 Human 1 1 ECDC (online)
Austria 2016 Human 2 2 ECDC (online)
2015 Human 3 3
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Country Year Species
No. total
cases(a)
No. conﬁrmed
cases(b)
Source
2014 Human 1 1
Bosnia and
Herzegovina
2014 Human 13 0 ECDC (online)
2013 Human 3 3
Bulgaria 2016 Human 1 1 ECDC (online)
2015 Human 2 0
Croatia 2016 Human 1 0 ECDC (online)
2013 Human 16 1 ECDC (online)
2012 Human 5 3 ECDC (online)
2013 Horses – 12 OIE (online)
Cyprus 2016 Human 1 1 ECDC (online)
Egypt 2016 Human 1 1 ECDC (online)
France 2015 Human 1 1 ECDC (online)
Former Yugoslav
Republic of Macedonia
2013 Human 1 ECDC (online)
2012 Human 6 1
Greece 2014 Human 15 13 HCDCP (online)
2014 Horses 4 4 OIE (online)
2013 Human 86 58 HCDCP (online)
2013 Horses – 15 OIE (online)
2012 Human 161 47 HCDCP (online)
2012 Horses – 15 OIE (online)
2011 Human 101 – HCDCP (online)
2011 Horses 23 – OIE (online)
2010 Human 261 – HCDCP (online)
2010 Horses 30 – OIE (online)
Hungary 2016 Human 39 16 ECDC (online)
2015 Human 18 13 ECDC (online)
2014 Human 11 3 ECDC (online)
2013 Human 31 6 ECDC (online)
2012 Human 12 7 ECDC (online)
2011 Human 3 – ECDC (online)
2010 Human 3 – ECDC (online)
Israel 2016 Human 80 47 ECDC (online)
2015 Human 123 89
2014 Human 17 7
2013 Human 63 28
2012 Human 59 31
2011 Human 39 –
Italy 2016 Human 71 71 ISS (online)
2016 Horses 51 51 IZSAM (online)
2015 Human 61 61 ISS (online)
2015 Horses 30 30 IZSAM (online)
2014 Human 24 24 ISS (online)
2014 Horses 27 27 IZSAM (online)
2013 Human 70 70 ISS (online)
2013 Horses – 50 IZSAM (online)
2012 Human 50 39 ISS (online)
2012 Horses – 63 IZSAM (online)
2011 Human – 15 ISS (online)
2011 Horses 197 – IZSAM (online)
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Country Year Species
No. total
cases(a)
No. conﬁrmed
cases(b)
Source
Kosovo 2012 Human 4 0 ECDC (online)
Former Yugoslav
Republic of Macedonia
2011 Human 4 – ECDC (online)
2011 Horses 10 – OIE (online)
Montenegro 2013 Human 4 – ECDC (online)
2012 Human 1 1
Morocco 2010 Horses 25 – OIE (online)
Palestine 2014 Human 1 1 ECDC (online)
2012 Human 2 1
Portugal 2016 Horses 1 1 OIE (online)
2015 Human 1 1 ECDC (online)
2015 Horses 4 4 OIE (online)
Romania 2016 Human 93 80 ECDC (online)
2015 Human 18 18 ECDC (online)
2014 Human 23 22 ECDC (online)
2013 Human 24 22 ECDC (online)
2012 Human 14 13 ECDC (online)
2011 Human 11 – ECDC (online)
2010 Human 52 – Sirbu et al. (2011)
2010 Horses 6 – OIE (online)
Russian Federation 2016 Human 135 135 ECDC (online)
2015 Human 39 39 ECDC (online)
2014 Human 29 – ECDC (online)
2013 Human 177 – ECDC (online)
2012 Human 447 – ECDC (online)
2011 Human 153 – ECDC (online)
2010 Human 480 – Promed (online)
Serbia 2016 Human 41 41 ECDC (online)
2015 Human 28 28
2014 Human 76 56
2013 Human 302 200
2012 Human 70 41
Spain 2016 Human 3 3 Andalucıa Ministry
of Agriculture
(online)
2016 Horses 70 70
2015 Horses 18 18
2013 Horses 40 –
2011 Horses 12 –
Syrian Arab Republic 2016 Human 2 1 ECDC (online)
Tunisia 2016 Human 1 1 ECDC (online)
2015 Horses 1 1 OIE (online)
2013 Human 6 6 ECDC (online)
2012 Human 63 33 ECDC (online)
2011 Human 3 – ECDC (online)
Turkey 2014 Horses 1 1 OIE (online)
2011 Human 3 – ECDC (online)
2010 Human 7 – ECDC (online)
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Transmissibility between humans
WNV is most commonly transmitted to humans by mosquitoes but additional routes of human-to-
human transmission have also been documented as blood transfusions, organ transplants, exposure in
a laboratory setting or the transmission from the mother to baby during pregnancy, delivery or
breastfeeding. It is important to note that these methods of transmission represent a very small
proportion of cases thus sufﬁcient to evoke only a sporadic occurrence of the disease.
Humans are dead-end hosts since are not able to infect mosquitoes during the viraemic phase of
the infection. Thus, the above-mentioned routes of direct transmission represent the main risk of
infection dissemination among community. Laboratory acquired infections have also been reported
(Campbell et al., 2002).
Parameter 3 – Human to human transmission is sufﬁcient to sustain sporadic cases or community-level
outbreak
WNV transmission through blood transfusion and organ transplantation is able to sustain
community-level outbreak.
Parameter 4 – Sporadic, endemic, epidemic, or pandemic potential
Neuroinvasive human cases are usually sporadic, occurring mainly in immunocompromised persons
or elderly.
The severity of human forms of the disease
Parameter 5 – Disability-adjusted life year (DALY)
Human infections are mostly asymptomatic. However, in some cases, they can exhibit a mild form
of the disease (less than 1%) with encephalitis, meningoencephalitis or meningitis mainly among
elderly or immunosupressed individuals (Go et al., 2014). As for most arthropod-borne diseases
causing fever syndromes worldwide, the cumulative impact of WNV on global disease burden has not
been fully assessed. Evaluations should include both the severe forms of the disease and the milder
clinical manifestations which may result in neurological and ophthalmologic complications (Carson
et al., 2006). WNV has been recognised able to induce a wide range of post-infection, long-term
sequelae with the recovery of the affected patients within two years from the infection (Murray et al.,
2008). However, a recent paper has emphasised that 40% of WNV-infected patients continued to
experience symptoms related to their WNV infection up to 8 years later demonstrating the health and
economic impact of a result of prolonged recovery, continued morbidity, and related disability (Murray
et al., 2014).
The availability of effective prevention or medical treatment in humans
Parameter 6 – Availability of medical treatment and their effectiveness (therapeutic effect and any
resistance)
There is no speciﬁc recommended treatment, other than supportive care, at present. Intensive care
and mechanical ventilation may be required in some cases. Various therapies including interferon,
antisense nucleotides and intravenous immunoglobulins (passive immunisation) are being tested in
clinical trials. While a few case reports suggest that some of these treatments may be promising,
larger studies are still lacking. Screening for new drugs that may inhibit WNV is underway.
Country Year Species
No. total
cases(a)
No. conﬁrmed
cases(b)
Source
Ukraine 2016 Human 1 0 ECDC (online)
2013 Human 1 –
2012 Human 12 –
2011 Human 8 –
(a): For EU countries, probable and conﬁrmed cases as per EU case deﬁnition (Commission Decision 2008/426/EC1).
(b): For EU countries, conﬁrmed cases as per EU case deﬁnition (Commission Decision 2008/426/EC).
1 Commission Decision of 28 April 2008 amending Decision 2002/253/EC laying down case deﬁnitions for reporting
communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the
Council (notiﬁed under document number C(2008) 1589) (Text with EEA relevance). OJ L 159, 18.6.2008, p. 46–90.
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Parameter 7 – Availability of vaccines and their effectiveness (reduced morbidity)
There are no vaccines available for human use in EU.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
The incubation period for equine WNV encephalitis following mosquito transmission is estimated to
be 3–15 days. A ﬂeeting viraemia of low virus titre precedes clinical onset (Bunning et al., 2002). WNV
encephalitis occurs in only a small per cent of infected horses; the majority of infected horses do not
display clinical signs (Ostlund et al., 2000). The disease in horses is frequently characterised by mild to
severe ataxia. Additionally, horses may exhibit weakness, muscle fasciculation and cranial nerve deﬁcits
(Cantile et al., 2000; Ostlund et al., 2000, 2001; Snook et al., 2001). Fever is an inconsistently
recognised feature. Treatment is supportive and signs may resolve or progress to terminal
recumbency. The mortality rate is approximately one out of three neurologically affected horses.
Many species of birds can become infected with WNV; the clinical outcome of infection is variable.
Some species appear resistant while others suffer fatal neurologic disease. WNV infection associated
with severe clinical signs have been described in several species of European wild birds (Bakonyi et al.,
2006; Hoﬂe et al., 2008; Jimenez-Clavero et al., 2008; Monaco et al., 2015).
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
CITES (online)
• Phoenicopteridae spp. (App. II)
• Falco rusticolus (App. I)
• Aquila adalberti (App. I)
• Falconiformes spp. (App. II)
Parameter 2 – Mortality in wild species
A number of outbreaks have been reported recently in Europe, Russia and parts of the Middle East.
Since 2004, one introduced Lineage 2 virus in Central Europe has affected signiﬁcant numbers of wild
and captive raptors (Erdelyi et al., 2007). Therefore, the potential for WNV to cause illness or deaths in
other European birds should be re-examined. Some virus lineages seem to have become endemic and
are spreading (CFSPH, 2013). Species known to be susceptible to this isolate include sparrow hawks
(Accipiter nisus), goshawks (Accipiter gentilis) and gyrfalcons (Falco rusticolus). The same virus was
isolated from a dead collared dove (Streptopelia decaocto) in Italy, during an outbreak characterised
by observed of mortality in collared doves and other species, including blackbirds. Different lineages of
the WNV have also been found occasionally in other dead birds including European robins (Erithacus
rubecula), raven (Corvus corax), common magpies (Pica pica), Eurasian jay (Garrulus glandarius),
house sparrows (Passer domesticus), black redstart (Phoenicurus ochruros), sedge warbler
(Acrocephalus schoenobaenus) and Savi’s warbler (Locustella luscinioides).
LaDeau et al. (2007) demonstrated a high impact on the abundance of seven species of North
American wild birds after the emergence of WNV in 1999. Host susceptibility, spatio-temporal
heterogeneity in pathogen transmission and other environmental impacts on populations were
accounted for using Bayesian modelling techniques. These seven species included two members of the
family Corvidae (American crow and blue jay), two from Turdidae (American robin and eastern bluebird),
two from Paridae (chickadees and tufted titmouse) and one from Troglodytidae (house wren). Also,
George et al. (2015) demonstrated signiﬁcant negative effects on survival of 47–49% bird species in
North America, using an extensive capture-recapture technique study of nearly two decades, combined
with recently developed models of WNV risk (George et al., 2015). The authors suggested that WNV in
the US has a signiﬁcant persistent effect on wild bird populations long after initial concerns had stopped.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
WNV is listed in the CDC list of potential bioterrorism agents.
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Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
WNV is not listed in the Encyclopaedia of Bioterrorism Defence of Australia Group.
Parameter 3 – Included in any other list of potential bio- agro-terrorism agents
WNV is not reported in any other list of potential bio-agro-terrorism agents.
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
Diagnostic tests, their type, accuracy and basis for WNF diagnosis are listed in Table 7.
Table 6: Test methods available for the diagnosis of WNV and their purpose (Source: (OIE, 2013))
Method
Purpose
Population
freedom
from
infection
Individual
animal freedom
from infection
Conﬁrmation
of clinical signs
Prevalence
of infection
Immune status in
individual animals
or populations
post-vaccination
Agent identiﬁcation
Nested RT-PCR – ** ** – –
Real-time RT-PCR – ** ** – –
Isolation in tissue
culture
– ** ** – –
Detection of immune response
IGM capture ELISA – – ** –
Plague reduction
neutralisation
** – * ** **
Serum neutralisation ** – * ** **
Immunohistochemistry – – * –
*** = recommended method; ** = suitable method; * = may be used in some situations, but cost reliability, or other factors
severity limits its application; – = not appropriate for this purpose.
Although not all of the rests listed as category *** have undergone formal validation, their routine nature and the fact that they
have been used widely without dubious results, makes them acceptable.
RT-PCR: reverse transcriptase polymerase chain reaction; IgM: immunoglobulin M; ELISA: enzyme linked immunosorbent assay.
Table 7: Diagnostic tests for WNV
Test Target Se Sp Matrix Reference Notes
NS1-antigen
protein
microarray
Antibodies 95% 100% Serum Cleton
et al. (in
press)
Differential diagnosis
of ﬂavivirus infections
in horses
Real-time
RT-PCR
Antigen From 1.5 to 15
copies per
reaction
100% Viral strains,
human samples
(cerebrospinal
ﬂuid, biopsies,
serum and
plasma) and
mosquito pools
Vazquez
et al.
(2016)
Speciﬁcity evaluated
using viral RNA from
a panel of different
ﬂaviviruses and other
encephalitic viruses
belonging to several
viral families
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Test Target Se Sp Matrix Reference Notes
Real-time
RT-PCR
Antigen 80 genome
copies
100% Viral strains
Lineages 1 and 2
Faggioni
et al.
(2014)
Speciﬁcity evaluated
using TBE, Usutu,
Dengue 1, Dengue 4,
YF, JEV
SYBR Green
I-based
real-time
RT-PCR
Antigen 20 copies 100% Human
serum/plasma
Kumar
et al.
(2014)
Speciﬁcity evaluated
using DEN-1–4, JEV,
YFV, SLEV
Antigen
capture
ELISA
Antigen 90% 98% Human serum Saxena
et al.
(2013)
Detection of NS1
antigen
Real-time
RT-PCR
Antigen 10 copies 100% Viral strains Barros
et al.
(2013)
Detection and
differentiation
between WNV and
JEV; speciﬁcity
evaluated using DEN-
1–4, JEV, YFV, ZIKAV,
Ntaya, TBEV, USUV,
Toscana, CHIKV
Real-time
RT-PCR
Antigen 1.26 TCID50/ml
for WNV-L1,
6.3 TCID50/ml
for WNV-L2
100% Tissue, feathers,
oropharyngeal
and cloacal
swabs and blood
from wild birds,
samples from
mice infected
experimentally
Del Amo
et al.
(2013)
Detection and
differentiation
between WNV and
USUV; speciﬁcity
evaluated using SLEV,
MVEV, JEV, BAGV,
DEN-1, TBEV, VEEV,
VSV, AIV, EIV, NDV,
AHS4
Competitive
ELISA
Antibodies 100% Wild birds:
79.5%
compared to
VNT
Sera from
mammals and
wild birds
Sotelo
et al.
(2011a)
Horses: 96.5%
compared to
VNT
South african
mammals:
79.5%
compared to
HAI
Giraffes: 67%
compared to
HAI
IgM capture
ELISA
Antibodies 91.7% 99.2% Horse sera Long et al.
(2006)
Real-time
RT-PCR
Antigen 2–4 genome
copies of WNV
100% Viral strains Eiden et al.
(2010)
In OIE manual. For
simultaneous
detection and
differentiation of
WNV Lineage 1 and
Lineage 2. Speciﬁcity
evaluated using TBEV,
YFV, JEV
Nested
RT-PCR
Antigen 10–8.0/100 lL ND Equine brain,
blood, and
cerebrospinal
ﬂuid; avian brain
tissues
Johnson
et al.
(2001)
In OIE manual
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Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
See Table 7.
3.1.4.2. Article 7(d)(ii) Vaccination
WNV vaccines approved by EMA are listed in Table 8.
Test Target Se Sp Matrix Reference Notes
Real-time
RT-PCR
Antigen 0.1 PFU 100% Human serum,
CSF, brain tissue,
mosquito pools,
and avian
tissues
Lanciotti
et al.
(2000)
In OIE manual.
Speciﬁcity evaluated
using DEN-2, JEV,
YFV, SLEV, Lacrosse
virus, Powassan virus,
MVE, WEEV, EEEV
RT-PCR: reverse transcriptase polymerase chain reaction; IgM: immunoglobulin M; ELISA: enzyme linked immunosorbent assay;
PFU: plaque-forming unit.
Table 8: Vaccines for horses authorised for commercialisation in the EU by the European Medicines
Agency (updated in October 2016) and their efﬁcacy as emerged from a systematic review
(updated to January 2016)
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YF-WN
IM Horses All EU Intervet
International
BV
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WNV
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WNV)
Inactivated
West Nile virus,
strain VM-2
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(21 days
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Horses All EU Zoetis
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Viruses could be isolated
from 8 out of 10 non-
vaccinated animals up to
14 days after challenge,
but only 1 vaccinated
animals. Sixty per cent
of the controls had to
be euthanised after
challenge compared to
none of the vaccinates.
From 10 non-vaccinated
animals, all presented,
up to 21 days after
challenge, pyrexia, head
tremors or muscle
fasciculations, and
anxiety, and 9 showed
mild paresis. In controls,
these numbers were 2,
2, 6 and 2, respectively
Experimental
trial
NA Bowen
et al.
(2014)
NA: data not available; IM: intramuscular.
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3.1.4.3. Article 7(d)(iii) Medical treatments
There is no speciﬁc recommended treatment, other than supportive care, at present.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
The biosecurity measures aiming at reducing the WNV spread are focused on controlling the
vectors primarily responsible for the viral transmission. Farm-to-farm movement of infected horses is
not effective to spread the disease since they are neither able to transmit the virus to biting
mosquitoes nor, directly, to vertebrates including humans.
To minimise the possibilities of contact between the vectors and receptive hosts, it is advisable to
use mosquito nets to avoid the vector entrance in the stables as well as the use of repellents on the
animals. Data related to the efﬁcacy of these substances has been detailed in Section 3.1.5.4
parameter 1.
To prevent any inter-human spread, the screening of blood and organs for transplantation in areas
with WNV circulation is a common measure.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
No speciﬁc measures are mentioned in the EU legislation for WNV outbreak control.
3.1.4.6. Article 7(d)(vi) Killing of animals
No speciﬁc measures are mentioned in the EU legislation for WNV outbreak control.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
No speciﬁc measures are mentioned in the EU legislation for WNV outbreak control.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
The major impact of WNV on animal health in the EU ecosystem is limited to the development of
clinical signs in horses and, to date, there are no reports of clinical illness in domestic bird species.
Thus, the major costs of WNV control in animals, namely horses, should include:
a) the cost of vaccination: primary vaccination consists of two doses, the second dose being
administered 3–6 weeks later, depending on the vaccine used;
b) the cost to prevent mosquitoes bites: keeping horses indoor is not be very effective against
Culex pipiens if additional measures such as mosquito nets or fans are not installed, as these
mosquitoes are also active indoors. The use of insecticides or repellents is also able to reduce
the possibilities for contact between the vectors and receptive hosts. Control of vectors can be
recommended to individuals and to public health authorities in case of a severe epidemic, but
the associated costs are difﬁcult to estimate since emergency aerial spraying, even if proven to
be effective in reducing mosquito populations and the number of human cases of WNV
infection in the US (Barber et al., 2010), would not be the ﬁrst option of vector control in MSs,
given the substantial environmental risks and not easily accepted by the population (Humblet
et al., 2016).
c) the costs of active surveillance activities, which may vary considerably between MSs. Usually
animal surveillance encompasses domestic solipeds (horses and donkeys), birds and other
animal species (e.g. cattle and farmed deer), as well as entomological surveillance activities.
The main objective of the surveillance in humans during the transmission period is to ensure
an immediate response in the implementation of the blood safety measures and the prevention
of human cases, and, on an annual basis, to improve and adapt the surveillance and
strengthen the preparedness.
d) WNV RNA screening of all blood donors in areas where the WNV circulation is in place. As an
example in Italy during the 2015 epidemics, a total of 316,614 WNV NAT screening tests were
conducted in blood donors in the affected provinces and 13 asymptomatic infected donors, were
identiﬁed. No donor or organ transplant recipients were positive for WNV among the 168 tested.
AHL assessment on West Nile fever
www.efsa.europa.eu/efsajournal 20 EFSA Journal 2017;15(8):4955
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
The control of the mosquito population through the intensive use of biocidal products, e.g. by aerial
spray is not easily accepted by the population (Humblet et al., 2016).
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
Since no speciﬁc measures are mentioned in the EU legislation for the WNV outbreak control, there
is no impact on the welfare of domestic animals of ofﬁcial control measures.
Parameter 2 – Wildlife depopulation as control measure
Wild bird depopulation is not a control measure applied in course of WNV outbreak and its efﬁcacy,
as emerged from epidemiological models, not ascertained since the potential reduction of bird
densities could enhance WNV transmission (Wonham et al., 2004).
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
In WNV-infected areas strategies must be implemented to reduce the circulation of the virus
through measures that modify the density of the vectors (reduction of stagnant water, performance of
adulticidal and larvicidal treatments) and to reduce the possibilities of contact between the vectors and
receptive hosts (application of repellent, mosquito netting, etc.). Among biocidal products, the use of
pyrethrin (6%) and piperonyl butoxide (60%) by aerial spray indicated that the odds of infection after
spraying were around 6 times higher in the untreated area than in treated areas, and that the
treatments successfully disrupted the WNV transmission cycle (Carney et al., 2008). Since Cx. pipiens
is considered to be the main vector of WNV in Europe a list of biocidal products targeting mosquito
control are reported in Table 9.
Table 9: Biocidal products targeting mosquito control (genus Culex), for which reports were found
in a systematic review of available treatments against the vectors of vector-borne
infections (papers published up to January 2016)
Active substance Reference
Intended use
(route investigated
in the study)
Study ﬁndings
Studies not targeting any particular host
Deltamethrin Marcombe et al.
(2011)
Fogging Efﬁcacy was assessed by monitoring mortality
rates of naturally resistant and laboratory
susceptible mosquitoes placed in sentinel cages.
Results showed high mortality rates of susceptible
sentinel mosquitoes (64%) while resistant
mosquitoes exhibited very low mortality (10%)
Vehicle-mounted
thermal foggers
(1 g/ha)
Studies focused on vector control in housing/environment
Deltamethrin Akogbeto et al.
(2010)
Indoor spraying Deterrence rate(a): Anopheles gambiae
(31.25%, 24.75%, 30 and 60 dpt; Culex sp. and
Mansonia sp. 30 dpt 46.15%)
Huts were treated with
insecticides. The
absorption of the walls
was 112 mL of
insecticide per m2 and
that of the ceiling
(polyethylene), the
entry slits, and the door
(painted metal) was in
total 53.13 mL/m2
Exophily rate(b): Anopheles gambiae (45.4%,
26.3%, 30 and 60 dpt; Culex sp. and Mansonia
sp. 30 dpt 33.3%)
Blood-feeding rate(c): Anopheles gambiae
(18.2%, 23.7%, 30 and 60 dpt; Culex sp. and
Mansonia sp. 30 dpt, 14.3%)
Immediate mortality(d): Anopheles gambiae
(32.7%, 15.8%, 30 and 60 dpt; Culex sp. and
Mansonia sp. 30 dpt, 8.5%)
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Active substance Reference
Intended use
(route investigated
in the study)
Study ﬁndings
Overall mortality(e): Anopheles gambiae (72.7%,
31.6%, 30 and 60 dpt; Culex sp. and Mansonia
sp. 30 dpt, 21%)
Deltamethrin Badolo et al.
(2014)
Mortality of mosquitoes was 90.5 (86–94)% in
unwashed nets (3 min exposure, 24-h
mortality), and remained above 90% after 5
washes. Average mortality after 10, 15 and 20
washes were 81 (75–86)%, 68.7 (63–75)% and
66.3 (60–72)%, respectively
Deltamethrin Dabire et al.
(2006)
Treated mosquito
nets
Mosquito entrance rate was 10-fold higher in
control houses than in houses with long lasting
impregnated nets (LLINs) and there was no
difference between the two tested net types.
Among mosquitoes found in the houses, 36%
were dead in LLIN houses compared to 0% in
control houses. Blood feeding rate was 80% in
control houses compared to 43% in LLIN
houses. The type of net did not signiﬁcantly
impact any of these parameters
Concentration of
55 mg/m2
Deltamethrin Darriet et al.
(2000)
Treated mosquito
nets
The 24-h mortality was 56% for Anopheles
gambiae females, and 45% for Culex spp.
females (compared to 4 and 6% in controls)Concentration of 25
mg/m2
Deltamethrin Moosa-Kazemi
et al. (2007)
Treated mosquito
nets
Recorded 24-h-mortality was 100% even after
9 months
Concentrations of 25
mg/m2
Deltamethrin Muller et al.
(2002)
Treated mosquito
nets
Mortality of mosquitoes was 97% in washed
nets, and reduced to 84%, 54% and 7% after
6, 12 and 18 months (with respective average
of times washed of 1.1, 1.9 and 3)
Concentrations from 55
mg/m2 (unwashed) to
1.6 mg/m2 (18 months
old and washed 3
times)
Deltamethrin Van Roey et al.
(2014)
Treated mosquito
nets
A positive control (commercial product
PermaNet 2.0, 55 mg a.i./m2) was able to kill
over 90% of mosquitoes (3 min exposure, 24-h-
mortality) for up to 30 months, while the
observed mortality with the experimental
product (Netprotect, 68 mg a.i./m2) was
85.7% after 12 months, and remained below
90%
Concentrations of 55
and 68 mg/m2
Diﬂubenzuron Cetin et al.
(2006)
Septic tank water
treatment
Recorded adult inhibition for Culex pipiens was
always 100% in the ﬁrst 2 weeks, for all
concentrations tested, and remained at 100%
for up to 4 weeks with 30 g/L, and 2 weeks
with 10 g/L
0.01, 0.02, and
0.03 mg (AI)/L, using a
25% wettable powder
or a 4% granular
formulation in
wastewater tank
Lambda-
cyhalothrin
Okumu et al.
(2012)
Indoor spraying Mortality (24-h mortality of
Anopheles arabiensis) was 90% after 30 days
but reduced to 35% after 60 days
0.03 g/m2 sprayed on
mud walls
Lambda-
cyhalothrin
Trout et al.
(2007)
Outdoors Spraying The reduction in Aedes albopictus in sites was of
89.5% compared to controls, and in laboratory
bioassays exposing mosquitoes to treated
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Active substance Reference
Intended use
(route investigated
in the study)
Study ﬁndings
leaves, mortality varies from 80% after 2 weeks,
to 35% after 8 weeks. In contrast, Culex spp.
were not reduced
Mist (concentration of
62.52 mL/L) directly
applied to vegetation in
the backyard of houses,
and other resting sites
Permethrin Rozendaal et al.
(1989)
Treated mosquito
nets
Cotton cloth impregnated with permethrin at a
rate of 0.5 g/m2 killed all Anopheles darlingi
females exposed for 2 min, but after the
material had been washed twice in soapy water
the bioassay mortality fell to only 21.4%.
Bioassays with Culex quinquefasciatus females
showed that sprayed nets were less effective
than nets impregnated by soaking (at equivalent
dosages of 0.16–1.34 g/m2)
Concentrations of
125–1,000 mg/m2
Permethrin Soleimani-
Ahmadi et al.
(2012)
Treated mosquito
nets
Mortality of mosquitoes was 100% in the ﬁrst
90 days, 92.4% (88–97) after 5 months, and
reduced to 81.6% (75–88) after 9 months, and
72.3% (65–79) after 12 monthsThe nets were blended
with 1,000 mg a.i/m2
(2%, w/w), and ﬁnal
concentrations varied
from 814 to 937 mg/m2
Studies focused on humans as the host species (personal protection)
DEET Soonwera and
Phasornkusolsill
(2015)
External use – topic/
spray
DEET was used as control when evaluating other
(non-ECHA approved) substances. The
formulation gave protection for up to 182 min,
and 98.5% protection from bites of Aedes
aegypti and Culex quinquefasciatus
DEET 20% (w/w), 0.1 mL
applied on a 3 9 10 cm
area on the ventral
portion of the forearm
DEET Gupta et al.
(1987)
Treated clothes and
topic applications of
repellent, in different
concentrations and
combinations
The ﬁeld trials were arranged in a four-way
factorial design which compared fabric types,
permethrin treatment and repellent treatments
over a 14-h test period. The repellent
formulations and the permethrin-treated clothing
used as one system provided better protection
(81% mortality) than the repellent formulations
or permethrin-treated clothing used separately
DEET + permethrin Mani et al.
(1991)
External use – soap Percentage repellency (reduction in biting rates)
was 96% for Culex vishnui, 89.6% for
Culex tritaeniorhynchus and 94.8% for
Culex pseudouishnui
Containing 20% DEET
and 5% permethrin
Metoﬂuthrin Dame et al.
(2014)
‘Clip-on’ spatial
repellent device
Efﬁcacy in reduction of
Anopheles quadrimaculatus, in 2 study years,
compared to control, were 16% and 8%)
31.20% 19% and 8% for Psorophora columbiae and
69% for Culex erraticus. Total mosquito
reduction was 13%
Metoﬂuthrin Revay et al.
(2013)
External use Biting on the arms of volunteers was reduced by
96.28% for Ae. albopictus, and by 94.94% for
Cx. pipiens
‘Clip-on’ metoﬂuthrin
(31.2%)
(a): Percentage of reduction in the number of mosquitoes caught in treated hut relative to the number caught in the control hut.
(b): Percentage of mosquitoes that have escaped the hut and have taken refuge in the veranda trap divided by the total number
of mosquitoes collected in the hut.
(c): Percentage of blood fed mosquitoes collected divided by the total of mosquitoes collected in veranda and hut.
(d): Percentage of dead mosquitoes collected in the morning compared to total mosquitoes collected in the hut.
(e): Immediate mortality plus delayed mortality recorded after 24 h.
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Biodiversity
Parameter 2 – Mortality in wild species
The main risk may be represented by the environmental residual of biocides which may interfere
with ecology of wild species.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about WNF (Table 10). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW
Panel, 2017a). Experts have been provided with information of the disease fact-sheet mapped into
Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017a). For details on the
interpretation of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel,
2017a).
3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Tables 11 and 12). The proportion of Y, N or na answers are reported,
followed by the list of different supporting views for each answer.
Table 10: Outcome of the expert judgement on the Article 5 criteria for West Nile fever
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof
exist in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due
to its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective
and proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)-A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal
health, or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger
to public and/or animal health in the Union
na
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
N
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
NC
B(v) The disease has or could have a signiﬁcant negative impact on the environment,
including biodiversity, of the Union
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or
not relevant to judge.
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Reasoning supporting the judgement
Supporting Yes:
• It is listed in OIE/CFSPH, there is public concern on the disease and the potential to create a
crisis.
• There have been examples of public health crisis in Romania in the 1990s, in Greece in 2010,
in Hungary and Russia following outbreaks in humans.
• US army indicates that virulent genes could be modiﬁed to increase pathogenicity for humans
and used as a weapon (since transmitted by mosquitoes).
• There were crisis in na€ıve areas, but not in endemic areas like France.
Supporting No:
• Some MSs do not have any WNV monitoring system in place, while others have been operating
systems for several years, e.g. Italy and Greece. The main objective of the surveillance in
humans during the transmission period is to ensure an immediate response in the
implementation of the blood safety measures and the prevention of human cases, and, on an
annual basis, to improve and adapt the surveillance and strengthen the preparedness. In Italy,
for example, though the repeated and constant WNV circulation, surveillance on blood samples
has been put in place and this also has not generated a crisis. Moreover, WNV circulation in
France have not generated crisis.
• The situation in the US is not related with bioterrorism.
• Every virus could be genetically modiﬁed and become a threat, a worst-case scenario exists for
every disease and should not be considered here.
Reasoning supporting the judgement
Supporting Yes:
• The North American experience shows that there is the potential for signiﬁcant impact on the
biodiversity.
Supporting No:
• There is no report of an impact of WNF at population level on endangered species in EU.
3.2.2. Outcome of the assessment of West Nile fever according to criteria of
Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017a), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 10, WNF
complies with all criteria of the ﬁrst set and with one criterion of the second set, therefore it is
considered eligible to be listed as laid down in Article 5 of the AHL.
Table 11: Outcome of the expert judgement related to criterion 5 B(iv)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(iv) The disease has the potential to generate a crisis or the
disease agent could be used for the purpose of bioterrorism
NC 83 17 0
NC: non-consensus; number of judges: 12.
Table 12: Outcome of the expert judgement related to criterion 5 B(v)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(v) The disease has or could have a signiﬁcant negative impact
on the environment, including biodiversity, of the Union
NC 82 18 0
NC: non-consensus; number of judges: 11.
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3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about WNF (Tables 13, 14, 15, 16 and 17). The expert judgement
was based on ICBA approach described in detail in the opinion on the methodology. Experts have been
provided with information of the disease fact-sheet mapped into Article 9 criteria (see supporting
information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion
of Article 9, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017a). For details on the
interpretation of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel,
2017a).
Table 13: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for West Nile fever
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present in only in a very limited part of the territory
of the Union
N
2.1 The disease is highly transmissible N
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4 (CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
4 (PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
NC
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
AHL assessment on West Nile fever
www.efsa.europa.eu/efsajournal 26 EFSA Journal 2017;15(8):4955
Table 14: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for West Nile fever
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are
free of the disease
Y
2.1 The disease is moderately to highly transmissible Y
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at point 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
Y
4 (CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
4 (PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
NC
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 15: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for West Nile fever
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character
Y
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss
N
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 18, 19
and 20). The proportion of Y, N or ‘na’ answers are reported, followed by the list of different
supporting views for each answer.
At least one criterion to be met by the disease:
In addition to the criteria set out above at point 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
Y
4(CI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
4(PI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
NC
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 16: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for West Nile fever
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated
by measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
N
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
Table 17: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for West Nile fever
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment (If a disease fulﬁls the criteria as in
Article 5, thus being eligible to be listed, consequently category E would apply.)
Y
Colour code: green = consensus (Yes/No).
AHL assessment on West Nile fever
www.efsa.europa.eu/efsajournal 28 EFSA Journal 2017;15(8):4955
Reasoning supporting the judgement
Supporting Yes:
• WNF may have a potential impact on animal health and consequently welfare if introduced in
naive populations in the absence of controls.
• The percentage of affected horses with severe clinical signs undergoes a signiﬁcant impact on
animal welfare.
Supporting No:
• Currently, there is no signiﬁcant impact on welfare although the virus is circulating in many
countries. It could have a potential impact in na€ıve populations.
• Although there has been extensive geographical expansion of the European territories with
WNV circulation, the number of clinical cases in horses remains very limited.
Reasoning supporting the judgement
Supporting Yes:
• The impact on wild birds could be potentially signiﬁcant, if there was a substantial increase in
outbreaks.
• Impacts of controls on the environment may be substantial.
• Supporting na:
• There are no data on the potential effect of vector control easures on the environment.
Reasoning supporting the judgement
Supporting Yes:
• There may be a potential impact, given the range of bird species potentially affected. Some
endangered species of, e.g. prey birds could disappear or be seriously threatened.
• The emergence of WNV strains more virulent for wild birds can affect larger numbers of
animals.
Table 18: Outcome of the expert judgement related to criterion 5(b)(PI) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5(b) The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
NC 83 17 0
NC: non-consensus; number of judges: 12.
Table 19: Outcome of the expert judgement related to criterion 5(c)(PI) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5(c) The disease has a signiﬁcant impact on the environment, due
to the direct impact of the disease OR due to the measures
taken to control it
NC 58 0 42
NC: non-consensus; number of judges: 12.
Table 20: Outcome of the expert judgement related to criterion 5(d)(PI) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5(d) The disease has a signiﬁcant impact on a long-term effect on
biodiversity or the protection of endangered species or
breeds, including the possible disappearance or long-term
damage to those species or breeds
NC 67 33 0
NC: non-consensus; number of judges: 12.
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Supporting No:
• There is an impact on individual animals, but no long-term effect on a population scale.
Furthermore there are periodic epidemic outbreaks, but the probability of long-term epidemics
in wild fauna is low.
3.3.2. Outcome of the assessment of criteria in Annex IV for West Nile fever for
the purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 11–17. According to the
assessment methodology (EFSA AHAW Panel, 2017a), a criterion is considered fulﬁlled when the
outcome is ‘Yes’. With respect to different type of impact where the assessment is divided into current
and potential impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’
and, in case of no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for WNF for the purpose of
categorisation as in Article 9 of the AHL is presented in Table 21.
According to the assessment here performed, WNF complies with the following criteria of the
Sections 1–5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a)–(e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment WNF complies with criteria 2.2 and 2.3, but
not with 1, 2.1 and 2.4. To be eligible for category A, a disease needs to comply
additionally with one of the criteria of the second set (3, 4, 5a–d) and WNF does not
comply with criteria 3, 4 and 5a and the assessment is inconclusive on compliance with
criteria 5b, 5c and 5d.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment WNF complies with all of them. To be eligible
for category B, a disease needs to comply additionally with one of the criteria of the second
Table 21: Outcome of the assessment of criteria in Annex IV for WNF for the purpose of
categorisation as in Article 9 of the AHL (CI = current impact; PI = potential impact)
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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set (3, 4, 5a–d) and WNF complies with criterion 3, but not with criteria 4 and 5a and the
assessment is inconclusive on compliance with criteria 5b, 5c and 5d.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment WNF complies with criteria 1, 2.1, 2.2 and
2.3, but not with 2.4. To be eligible for category C, a disease needs to comply additionally
with one of the criteria of the second set (3, 4, 5a–d) and WNF complies with criterion 3,
but not with criteria 4 and 5a and this assessment is inconclusive on compliance with
criteria 5b, 5c and 5d.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or
5 of Annex IV of the AHL and with the speciﬁc criterion D of Section 4. WNF does not
comply with the latter.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating to
animal health, animal welfare, human health, the economy, society or the environment. The
latter is applicable if a disease fulﬁls the criteria as in Article 5, with which WNF complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
WNF. The Article 8(3) criteria are about animal species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.2 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017a), the main animal species to be listed for WNF according to the criteria of
Article 8(3) are several species of birds and mammals, displayed in details in Table A.1 in Appendix A,
as susceptible species. Several bird species belonging to the families of Corvidae, Passeridae and
Fringillidae (order of Passeriformes) and to the family of Columbidae (order Columbiformes) can be
considered reservoir species for WNV in Europe, details are shown in Table B.1 in Appendix B. The
main vectors are some species of mosquitoes belonging to the genera Culex, Aedes and Coquillettidia
(family Culicidae, order Diptera). The vector species are listed in https://efsa.maps.arcgis.com/apps/Ma
pJournal/index.html?appid=512a03aa8df84d54a51bcb69d1b62735 (EFSA AHAW Panel, 2017b).
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, WNF complies with all criteria of the ﬁrst set and
with one criterion of the second set and therefore can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, WNF meets the criteria as in Sections 2 and 5 of
Annex IV of the AHL, for the application of the disease prevention and control rules referred to
in points (b) and (e) of Article 9(1) of the AHL.
2 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors, the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for WNF according to Article 8(3) of the AHL are, as susceptible species, several orders
of birds and mammals and two orders of reptiles, as reported in Table A.1 in Appendix A of
the present document. Reservoirs are several bird species belonging to the families of
Corvidae, Passeridae and Fringillidae (order of Passeriformes) and to the family of Columbidae
(order Columbiformes). Vectors are some species of mosquitoes belonging to the genera
Culex, Aedes and Coquillettidia (family Culicidae, order Diptera).
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Appendix A – Animal species infected naturally and experimentally by WNV
Table A.1: Naturally susceptible wildlife species (or family/orders)
Class Order Family Species
Aves Anseriformes Anatidae Wood duck-Aix sponsa, Eurasian wigeon-
Anas penelope (c), bronze-winged duck (spectacled
duck)-Anas specularis (c), canvasback-
Aythya valisineria, Canada goose-
Branta Canadensis, barnacle goose-
Branta leucopsis (c)(a), emperor goose-Chen
canagica (c), greater Magellan goose (Andean
goose)-Chloephagapicta leucoptera (c)(a),
Abyssinian blue-winged goose-
Cyanochen cyanopterus (c)(a), tundra swan-
Cygnus columbianus (c), trumpeter swan-Cygnus
Cygnus buccinator (c)(a), mute swan-Cygnus olor,
Rosy-billed pichard-Netta peposaca (c)(a), ruddy
duck-Oxyura jamaicensis
Apodiformes Apodidae Chimney swift-Chaetura pelagica
Trochilidae Ruby-throated hummingbird-Archilochus colubris
Caprimulgiformes Caprimulgidae Common nighthawk-Chordeiles minor
Casuariiformes Dromaiidae Emu-Dromaius novaehollandiae (c)
Charadriiformes Haradriidae Ruddy turnstone-Arenaria interpres, killdeer-
Charadrius vociferous, piping plover-Charadrius
melodus
Laridae European herring gull-Larus argentatus, laughing
gull-Larus atricilla, ring-billed gull-Larus
delawarensis, great black-backed gull-Larus
marinus, black skimmer-Rhynchops niger, grey
gull-Larus modestus (c)(a), Inca tern-Larosterna
inca (c)(a)
Ciconiformes Ardeidae Yellow-crowned night-heron-Nyctanassa violacea
(c), black-crowned night-heron-Nycticorax
nycticorax (c), great blue heron-Ardea Herodias,
green heron-Butorides virescens, least bittern-
Ixobrychus exilis
Cathartidae Turkey vulture-Cathartes aura, black vulture-
Coragyps atratus, king vulture-Sarcoramphus papa
(c)(a)
Ciconiidae Saddle-billed stork-Ephippiorhynchos senegalensis
(c)(a), marabou stork-Leptopilos crumeniferus (c)
(a), lesser adjutant-Leptoptilos javanicus (c)(a)
Phoenicopteridae Chilean ﬂamingo-Phoenicopterus chilensis (c),
greater ﬂamingo-Phoenicopterus ruber ruber (c)
Threskiornithidae Scarlet ibis-Eudocimus ruber (c), northern bald
ibis-Geronticus eremita (c)(a)
Columbiformes Columbidae White-crowned pigeon-Columba leucocephala, rock
dove-Columba livia, Mauritius pink pigeon-Columba
mayeri (c)(a), common ground-dove-Columbina
passerine, Eurasian collared-dove-Streptopelia
decaocto, white-winged dove-Zenaida asiatica,
mourning dove-Zenaida macroura, Luzon bleeding-
heart-Gallicolumba luzonica (c)(a), Inca dove-
Columbina inca
Coraciiformes Alcedinidae Belted kingﬁsher-Ceryle alcyon
Cuculiformes Cuculidae Yellow-billed cuckoo-Coccyzus americanus
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Falconiformes Accipitridae Cooper’s hawk-Accipiter cooperii, Northern
goshawk-Accipiter gentilis, sharp-shinned hawk-
Accipiter striatus, golden eagle-Aquila chrysaetos,
red-tailed hawk-Buteo jamaicensis, rough-legged
hawk-Buteo lagopus (c), red-shouldered hawk-
Buteo lineatus, broad-winged hawk-Buteo
platypterus, Swainson’s hawk-Buteo swainsoni,
Northern harrier-Circus cyaneus, swallow-tailed
kite-Elanoides forﬁcatus, bald eagle-Haliaeetus
leucocephalus, Mississippi kite-Ictinia
mississippiensis, Osprey-Pandion haliaetus, Harris’s
hawk-Parabuteo unicinctus (c)
Falconidae Merlin-Falco columbarius, prairie falcon-Falco
mexicanus, peregrine falcon-Falco peregrinus,
American kestrel-Falco sparverius
Galliformes Numididae Crested guineafowl-Guttera pucherani (c)(a)
Odontophoridae Northern bobwhite-Colinus virginianus
Phasianidae Chukar-Alectoris chukar (c)(a), ruffed grouse-
Bonasa umbellus, green junglefowl-Gallus varius (c)
(a), Himalayan monal-Lophophorus impeyanus (c),
Bulwer’s pheasant-Lophura bulweri (c)(a), ring-
necked pheasant-Phasianus colchicus, mountain
peacock-pheasant-Polypectron inopinatum (c)(a),
crested partridge-Rollulus roulroul (c)(a), Blyth’s
tragopan-Tragopan blythii (c), argus pheasant
(unspeciﬁed)-various (c)(a), greater sage grouse-
Centrocerus urophasianus
Gaviiformes Gaviidae Common loon-Gavia immer
Gruiformes Gruidae Demoiselle crane-Anthropoides virgo (c)(a), West
African crowned crane-Balearica pavonina pavonina
(a), wattled crane-Bugeranus carunculatus (c)(a),
whooping crane-Grus americana (c)(a), Mississippi
sandhill crane-Grus canadensis pulla (c), red-
crowned crane-Grus japonensis (c)(a), Siberian
crane-Grus leucogeranus (c)(a), hooded crane-Grus
monacha (c)(a), white-naped crane-Grus vipio (c)(a)
black-necked crane-Grus nigricollis (c)(a)
Rallidae Virginia rail-Rallus limicola
Musophagiformes Musophagidae Lady Ross’s turaco-Musophaga rossae (c)(a)
Passeriformes Bombycillidae Cedar waxwing-Bombycilla cedrorum
Cardinalidae Northern cardinal-Cardinalis cardinalis, blue
grosbeak-Guiraca caerulea (a), rose-breasted
grosbeak-Pheucticus ludovicianus, dickcissel-Spiza
americana
Corvidae Western scrub-jay-Aphelocoma californica,
American crow-Corvus brachyrhynchos, common
raven-Corvus corax, ﬁsh crow-Corvus ossifragus,
blue jay-Cyanocitta cristata, Steller’s jay-Cyanocitta
stelleri, black-billed magpie-Pica hudsonia (c)
Emberizidae Song sparrow-Melospiza melodia, savannah
sparrow-Passerculus sandwichensis, fox sparrow-
Passerella iliaca, Eastern towhee-Pipilo
erythrophthalmus, ﬁeld sparrow-Spizella pusilla
Estrildidae Zebra ﬁnch-Taeniophygia guttata (c)
AHL assessment on West Nile fever
www.efsa.europa.eu/efsajournal 41 EFSA Journal 2017;15(8):4955
Class Order Family Species
Fringillidae American goldﬁnch-Carduelis tristis, house ﬁnch-
Carpodacus mexicanus, purple ﬁnch-Carpodacus
purpureus, evening grosbeak-Coccothraustes
vespertinus, European goldﬁnch-Carduelis
carduelis (c)
Hirundinidae Barn swallow-Hirundo rustica, purple martin-Progne
subis, tree swallow-Tachycineta bicolor
Icteridae Red-winged blackbird-Agelaius phoeniceus, rusty
blackbird-Euphagus carolinus, Brewer’s blackbird-
Euphagus cyanocephalus, Baltimore oriole-Icterus
galbula, brown-headed cowbird-Molothrus ater,
boat-tailed grackle-Quiscalus major, great-tailed
grackle-Quiscalus mexicanus, common grackle-
Quiscalus quiscula
Laniidae Loggerhead shrike-Lanius ludovicianus
Mimidae Gray catbird-Dumetella carolinensis, Northern
mockingbird-Mimus polyglottos, brown thrasher-
Toxostoma rufum
Paridae Tufted titmouse-Baeolophus bicolor, varied tit-Parus
varius (c), black-capped chickadee-Poecile
atricapilla, Carolina chickadee-Poecile carolinensis
Parulidae Black-throated blue warbler-Dendroica caerulescens,
yellow-rumped warbler-Dendroica coronate, yellow
warbler-Dendroica petechial, blackpoll warbler-
Dendroica striata, common yellowthroat-Geothlypis
trichas, Kentucky warbler-Oporornis formosus,
Northern parula-Parula Americana, ovenbird-Seiurus
aurocapillus, Northern waterthrush-Seiurus
noveboracensis, Nashville warbler-Vermivora
ruﬁcapilla, Canada warbler-Wilsonia Canadensis,
hooded warbler-Wilsonia citrina
Passeridae House sparrow-Passer domesticus
Sylviidae White-crested laughingthrush-Garrulax leucolophus
(c)(a)
Sittadae White-breasted nuthatch-Sitta carolinensis
Sturnidae European starling-Sturnus vulgaris
Thraupidae Palm tanager-Thraupis palmarum (c)
Troglodytidae Carolina wren-Thryothaurus ludovicianus, winter
wren-Troglodytes troglodytes
Turdidae Veery-Catharus fuscescens, hermit thrush-Catharus
guttatus, gray-cheeked thrush-Catharus minimus,
Swainson’s thrush-Catharus ustulatus, wood thrush-
Hylocichla mustelina, Eastern bluebird-Sialia sialis,
American robin-Turdus igratorius
Tyrannidae Traill’s ﬂycatcher-Empidonax traillii/alnorum, Eastern
phoebe-Sayornis phoebe, scissor-tailed ﬂycatcher-
Tyrannus forﬁcatus, Eastern kingbird-Tyrannus
tyrannus
Vireonidae Black-whiskered vireo-Vireo altiloquus, warbling
vireo-Vireo gilvus, red-eyed vireo-Vireo olivaceus
Pelecaniformes Pelecanidae American white pelican-Pelecanus erythrorhynchos,
brown pelican-Pelicanus occidentalis (c)(a), double-
crested cormorant-Phalacrocorax auritus, guanay
cormorant-Phalacrocorax bougainvillei (c)
Piciformes Picidae Red-headedwoodpecker-Melanerpes erythrocephalus,
downywoodpecker-Picoides pubescens, yellow-bellied
sapsucker-Sphyrapicus varius
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Podicipediformes Podicipedidae Pied-billed grebe-Podilymbus podiceps
Psittaciformes Cacatuidae Cockatoo (unspeciﬁed)-Cacatua spp. (c), cockatiel-
Nymphicus hollandicus (c)
Psittacidae Red-crowned parrot-Amazona viridigenalis (c),
macaw (unspeciﬁed)-Ara spp. (c), budgerigar-
Melopsittacus undulatus (c), lorikeet spp.-
Tricheglossus spp. (c)
Sphenisciformes Spheniscidae African penguin-Spheniscus demersus (c), Magellan
penguin-Spheniscus humboldti (c)(a)
Strigiformes Strigidae Northern saw-whet owl-Aegolius acadicus, boreal
owl-Aegolius funereous (c), short-eared owl-Asio
ﬂammeus, Verreaux’s eagle owl (milky eagle owl)-
Bubo lacteus (c)(a), great horned owl-Bubo
virginianus, snowy owl-Nyctea scandiaca (c),
Eastern screech owl-Otus asio, tawny owl-Strix
aluco (c), great grey owl-Strix nebulosa (c), spotted
owl-Strix occidentalis (c), barred owl-Strix varia,
Northern hawk owl-Surnia ulula (c)
Tytonidae Barn owl-Tyto alba
Struthioniformes Struthionidae Ostrich-Struthio camelis (c)(a)
Mammalia Artiodactyla Bovidae Mountain goat-Oreamnos americanus (c)
Camelidae Llama-Lama glama (c), alpaca-Lama pacos (c)
Cervidae White-tailed deer-Odocoileus virgninianus, reindeer-
Rangifer tarnadus (c), mule deer-Odocoileus
hemionus
Suidae Babirusa-Babyrousa babyrousa (c)(a)
Carnivora Canidae Timber wolf-Canis lupus (c)
Mustelidae Striped skunk-Mephitis mephitis
Phocidae Harbor seal-Phoca vitulina (c)
Procyonidae Red panda-Ailurus fulgens fulgens (c)(a)
Ursidae Black bear-Ursus americanus (a)
Chiroptera Vespertilionidae Big brown bat-Eptesicus fuscus, little brown bat-
Myotis lucifugus
Perissodactyla Rhinocerotidae Great Indian rhinoceros-Rhinoceros unicornis (c)(a)
Primates Cercopithecidae Barbary macaque-Macaca sylvanus (c)
Lemuridae Ring-tailed lemur-Lemur catta (c)
Proboscidea Elephantidae Indian (Asian) elephant-Elephas maximus indicus
(c)(a)
Rodentia Sciuridae Gray squirrel-Sciurus carolinensis, fox squirrel-
Sciurus niger, Eastern chipmunk-Tamias striatus
Reptilia Crocodylia Alligatoridae American alligator-Alligator mississippiensis (c)
Squamata Varanidae Crocodile monitor-Varanus salvadorii (c)(a)
(c) Denotes either a captive or farmed animal(s). Virus or viral RNA was detected in animal tissue unless followed by an (a),
which denotes detectable antibodies only have been reported (Source: USGS, National Wildlife Health Center (USGS, online)).
Table A.2: Naturally susceptible domestic species (or family/orders)
Class Order Family Species
Aves Galliformes Phasianidae Domestic chicken (Red junglefowl)-Gallus gallus
Turkey (domestic and wild)-Meleagris gallopavo
Anseriformes Anatidae Mallard-Anas platyrhynchos
Domestic goose-Anser chinensis (c)(a)
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Mammalia Artiodactyla Bovidae Domestic cattle-Bos taurus
Domestic (suffolk) sheep-Ovis aries
Carnivora Canidae Domestic dog-Canis familiaris
Felidae Domestic cat (feral)-Felis catus
Lagomorpha Leporidae Domestic rabbit-Oryctolagus cuniculus
Perissodactyla Equidae Domestic horse-Equus equus przewalski caballus
Donkey-Equus asinus
Mule
(c) Denotes either a captive or farmed animal(s). Virus or viral RNA was detected in animal tissue unless followed by an (a),
which denotes detectable antibodies only have been reported (Source: USGS, National Wildlife Health Center (USGS, online)).
Table A.3: Summary outcomes of experimental infections of West Nile virus performed in wild birds
(adapted from Perez-Ramırez et al. (2014))
Order Family Species Strain Mortality Viraemia Distribution References
Passeriformes Turdidae American robin
(Turdus
migratorius)
NY < 20% H AM Komar et al.
(2003),
VanDalen et al.
(2013)
Swainson’s thrush
(Catharus
ustulatus)
NY < 20% M AM Owen et al.
(2006)
Clay-coloured
thrush (Turdus
grayi)
TEC/TAB 20–50%/
< 20%
M AM Guerrero-
Sanchez et al.
(2011)
Corvidae Carrion crow
(Corvus corone)
FR/ISR 20–50%/
> 50%
L EUR/ASIA Dridi et al.
(2013)
American crow
(Corvus
brachyrhynchos)
NY/TEX/MEX > 50% H AM McLean et al.
(2001), Komar
et al. (2003),
Brault et al.
(2004),
Weingartl et al.
(2004), Kinney
et al. (2006),
Kipp et al.
(2006), Brault
et al. (2007,
2011), Nemeth
et al. (2011)
KEN/KUN 20–50%/
< 20%
M
Fish crow (Corvus
ossifragus)
NY > 50% H AM Komar et al.
(2003), Kipp
et al. (2006),
Nemeth et al.
(2011)
Little raven
(Corvus mellori)
NY < 20% M OCE Bingham et al.
(2010)KUN < 20% L
Hooded crow
(Corvus cornix)
EGY > 50% H EUR/ASIA/
AFR
Work et al.
(1955)
Western scrub-jay
(Aphelocoma
californica)
NY > 50% H AM Reisen et al.
(2005)
Blue jay
(Cyanocitta
cristata)
NY > 50% H AM Komar et al.
(2003),
Weingartl et al.
(2004)
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Black-billed magpie
(Pica hudsonia)
NY > 50% H AM Komar et al.
(2003)
Jungle crow
(Corvus
macrorhynchos)
NY > 50% H ASIA Shirafuji et al.
(2008)
Passeridae House sparrow
(Passer
domesticus)
NY/CA/KEN/
EGY/TAB/
TEC/SP/IT09
> 50% H WORLDWIDE Work et al.
(1955), Komar
et al. (2003,
2005), Langevin
et al. (2005),
Reisen et al.
(2005, 2006),
Nemeth et al.
(2008), LaPointe
et al. (2009);
Nemeth et al.
(2009a,b), Brault
et al. (2011),
Guerrero-
Sanchez et al.
(2011), Wheeler
et al. (2012),
Del Amo et al.
(2014)
TEX/KUN/
IT08
< 20% M
MEX < 20% L
Cape sparrow
(Passer
melanurus)
SA* Und L AFR McIntosh et al.
(1969)
Icteridae Red-winged
blackbird
(Agelaius
phoeniceus)
NY < 20% M/L AM Komar et al.
(2003), Reisen
and Hahn
(2007), Nemeth
et al.(2009b)
Brown-headed
cowbird
(Molothrus
ater)
NY < 20% L AM Reisen et al.
(2006), Reisen
and Hahn
(2007)
Brewer’s blackbird
(Euphagus
cyanocephalus)
NY < 20% H AM Reisen et al.
(2006), Reisen
and Hahn
(2007)
Tricolored
blackbird
(Agelaius
tricolor)
NY < 20% H AM Reisen and Hahn
(2007)
Common grackle
(Quiscalus
quiscula)
NY 20–50% H AM Komar et al.
(2003)
Great-tailed
grackle
(Quiscalus
mexicanus)
TAB/TEC > 50%/
20–50%
H AM Guerrero-
Sanchez et al.
(2011)
Bay-winged
cowbird
(Agelaioides
badius)
ARG < 20% L AM Diaz et al.
(2011)
Shiny cowbird
(Molothrus
bonariensis)
ARG < 20% L AM Diaz et al.
(2011)
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Emberizidae Song sparrow
(Melospiza
melodia)
NY < 20% M AM Reisen and Fang
(2007)
White-crowned
sparrow
(Zonotrichia
leucophrys)
NY Und na AM Reisen et al.
(2006)
Fringillidae Hawai’i ‘amakihi
(Hemignathus
virens)
NY 20–50% H AM LaPointe et al.
(2009)
House ﬁnch
(Haemorhous
mexicanus)
NY > 50% H AM Komar et al.
(2003), Reisen
et al. (2005),
Fang and Reisen
(2006), Reisen
et al. (2006)
Ploceidae African masked
weaver (Ploceus
velatus)
SA* Und M AFR McIntosh et al.
(1969)
Red-billed quelea
(Quelea quelea)
SA* Und L AFR McIntosh et al.
(1969)
Red bishop
(Euplectes orix)
SA* Und M AFR McIntosh et al.
(1969)
Hirundinidae Cliff swallow
(Petrochelidon
pyrrhonota)
NY < 20% M AM Oesterle et al.
(2009, 2010)
Mimidae Gray catbird
(Dumetella
carolinensis)
NY < 20% M AM Owen et al.
(2006)
Northern
mockingbird
(Mimus
polyglottos)
NY < 20% H AM Komar et al.
(2005)
Sturnidae European starling
(Sturnus vulgaris)
NY < 20% M WORLDWIDE Komar et al.
(2003); Reisen
et al. (2006)
Cardinalidae Northern cardinal
(Cardinalis
cardinalis)
NY < 20% H AM Komar et al.
(2005); Owen
et al. (2012)
Paridae Tufted titmouse
(Baeolophus
bicolor)
NY > 50% H AM Kilpatrick et al.
(2013)
Troglodytidae Carolina wren
(Thryothorus
ludovicianus)
NY 20–50% H AM Kilpatrick et al.
(2013)
Falconiformes Falconidae Gyrfalcon (Falco
rusticolus)
AUS* 20–50% H AM/EUR/AS Ziegler et al.
(2013)NY 20–50% M
Hybrid falcon
(Falco rusticolus x
Falco cherrug)
NY < 20% L WORLDWIDE Busquets et al.
(2012)
American kestrel
(Falco sparverius)
NY < 20% H AM Komar et al.
(2003), Nemeth
et al. (2006a)
Common kestrel
(Falco tinnunculus)
EGY < 20% L EUR/AS/AFR Work et al.
(1955)
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Accipitriformes Accipitridae Red-tailed hawk
(Buteo
jamaicensis)
NY < 20% H AM Nemeth et al.
(2006a)
Strigiformes Tytonidae Barn owl
(Tyto alba)
NY < 20% L WORLDWIDE Nemeth et al.
(2006a)
Strigidae Great horned owl
(Bubo virginianus)
NY < 20% H AM Komar et al.
(2003), Nemeth
et al. (2006a)
Eastern screech-
owl
(Megascops asio)
NY > 50% H AM Nemeth et al.
(2006a)
Galliformes Odontophoridae California quail
(Callipepla
californica)
NY < 20% L AM Reisen et al.
(2005, 2006)
Gambel’s quail
(Callipepla
gambelii)
NY < 20% L AM Reisen et al.
(2006)
Northern bobwhite
(Colinus
virginianus)
NY < 20% L AM Komar et al.
(2003)
Phasianidae Red-legged
partridge
(Alectoris rufa)
SP/MO 20–50%/
> 50%
H EUR Sotelo et al.
(2011b)
NY > 50% L Escribano-
Romero et al.
(2013)
Japanese quail
(Coturnix japonica)
NY < 20% L WORLDWIDE Komar et al.
(2003)
Ring-necked
pheasant
(Phasianus
colchicus)
NY < 20% L WORLDWIDE Komar
et al.(2003)
Greater sage-
grouse
(Centrocercus
urophasianus)
NY > 50% M AM Clark et al.
(2006)
Pelecaniformes Ardeidae Rufous night-heron
(Nycticorax
caledonicus)
KUN < 20% L OCE Boyle et al.
(1983b,a)
Little egret
(Egretta garzetta)
KUN < 20% L EUR/AS/AFR/
OCE
Boyle et al.
(1983a,b)
Intermediate
heron
(Mesophoyx
intermedia)
KUN < 20% L AFR/AS Boyle et al.
(1983a,b)
Cattle egret
(Bubulcus ibis)
SA*/EGY Und/
< 20%
L WORLDWIDE Work et al.
(1955);
McIntosh et al.
(1969)
Threskiornithidae African sacred ibis
(Threskiornis
aethiopicus)
SA* Und L AFR/AS McIntosh et al.
(1969)
Columbiformes Columbidae Rock pigeon
(Columba livia)
SA*/NY/TEC/
TAB
Und/
< 20%
L WORLDWIDE McIntosh et al.
(1969);
Guerrero-
Sanchez et al.
(2011)
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Ring-necked dove
(Streptopelia
capicola)
SA* Und L AFR McIntosh et al.
(1969)
Eurasian collared-
dove (Streptopelia
decaocto)
NY/CO < 20%/
< 20%
M AM/EUR/AS/
AFR
Panella et al.
(2013)
Laughing dove
(Spilopelia
senegalensis)
SA*/EGY Und/
< 20%
L AFR/AS Work et al.
(1955),
McIntosh et al.
(1969)
Common ground-
dove (Columbina
passerina)
NY Und na AM Reisen et al.
(2006, 2008)
Mourning dove
(Zenaida
macroura)
NY < 20% M AM Komar et al.
(2003), Reisen
et al. (2005,
2006)
Picui ground-dove
(Columbina picui)
ARG < 20% M AM Diaz et al.
(2011)
Gruiformes Rallidae American coot
(Fulica americana)
NY < 20% L AM Komar et al.
(2003)
Crested coot
(Fulica cristata)
SA* Und L AFR/EUR McIntosh et al.
(1969)
Gruidae Sandhill crane
(Grus canadensis)
NY < 20% L AM Olsen et al.
(2009)
Anseriformes Anatidae Common goose
(Anser anser)
SA* > 50% M WORLDWIDE Banet-Noach
et al. (2003)
Canada goose
(Branta
canadensis)
NY < 20% M AM/EUR Komar et al.
(2003)
Mallard (Anas
platyrhynchos)
NY < 20% H WORLDWIDE Komar et al.
(2003)
Yellow-billed duck
(Anas undulata)
SA* Und L AFR McIntosh et al.
(1969)
Red-billed teal
(Anas
erythrorhyncha)
SA* Und L AFR McIntosh et al.
(1969)
Southern pochard
(Netta
erythrophthalma)
SA* Und L AFR McIntosh et al.
(1969)
Charadriiformes Charadriidae Killdeer
(Charadrius
vociferus)
NY < 20% H AM Komar et al.
(2003)
Laridae Ring-billed gull
(Larus
delawarensis)
NY > 50% H AM Komar et al.
(2003)
Psittaciformes Psittacidae Monk parakeet
(Myiopsitta
monachus)
NY < 20% L AM Komar et al.
(2003)
Budgerigar
(Melopsittacus
undulatus)
NY < 20% L OCE Komar et al.
(2003)
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Piciformes Picidae Northern ﬂicker
(Colaptes
auratus)
NY < 20% M AM Komar et al.
(2003)
CA: California 04; NY: New York 99; CO: Colorado 08; SA: South Africa; ARG: Argentina 06; EGY: Egypt; KUN: Kunjin; SP: Spain
07; MO: Morocco 03; AUS: Austria 09; MEX: Mexico 03; TEX: Texas 03; KEN: Kenya 3829; FR: France 00; ISR: Israel 98; TEC:
Tecato (Mexico); TAB: Tabasco (Mexico); IT08: Italy 08; IT09: Italy 09.* Lineage 2.
L: Low viraemia (mean peak viraemia ≤ 104 PFU/mL); M: Medium viraemia (mean peak viraemia 104–106 PFU/mL); H: High
viraemia (mean peak viraemia > 106 PFU/mL); na: Data not available.
AFR: Africa; AM: America; AS: Asia; EUR: Europe; OCE: Oceania.
Und: Undetermined.
Table A.4: Summary outcomes of systematic review of experimental infections of domestic animals
with WNV (papers published up to January 2016)
Species References
Number
of animal
groups
(a)
Agent detection(b)
Observation of
clinical signs(c)
Clinical signs
(and number of
groups in which
were reported)Min day Max day Min day Max day
Cats Austgen et al.
(2004)
3 (19
animals)
Virus isolation
from blood:
1 (0.5–3)
Virus isolation
from blood:
7 (4.5–8)
1 6 No clinical signs
observed (2), fever
(1), depression/
apathy (1)
0 dead animals
Dogs Austgen et al.
(2004), Karaca
et al. (2005)
2 (19
animals)
Virus isolation
from blood:
1.3 (0.5–2)
Virus isolation
from blood:
5.3 (4.5–6)
1 1 No clinical signs
observed (1),
fever (1)
0 dead animals
Horses Bunning et al.
(2002),
Shirafuji et al.
(2009),
Castillo-Olivares
et al. (2011)
4 (17
animals)
Virus isolation
from blood
(3 groups):
3(1–4)
Virus isolation
from blood
(3 groups):
6 (6–7)
6.5 (3–8) 10 (9–11) No clinical signs
observed (1),
twitching/tremors
(1), neurological
signs (2), fever (1)
PCR from
blood (1
group): 3
PCR from
blood
(1 group): 7
1 dead animal in
1 group
Pigs Teehee et al.
(2005)
2 (12
animals)
Virus isolation
from blood:
1.5 (1.5–4.5)
Virus isolation
from blood:
5 (4.5–5)
Not
reported
No clinical signs
observed (1), not
reported (1)
0 dead animals
Rabbits Suen et al.
(2015)
2 (27
animals)
Not reported 1 Not
reported
No clinical signs
observed (1),
fever (1)
0 dead animals
Sheep Barnard and
Voges (1986)
1 (2
animals)
Virus isolation
from blood: 3
Virus isolation
from blood: 11
3 3 Fever
(a): ll data were analysed at animal group level, reﬂecting the animal groups followed and reported in the individual references.
Some references reported more than one animal group.
(b): Min = ﬁrst day (in dpi) that pathogen/RNA was detected in a sample for each reported animal group; Max = last day (in dpi)
that virus/RNA was detected in a sample for each reported animal group. Min and Max were recorded individually for each
animal group, and median (min-max) for each of those values were calculated from all group data (each group representing
one observation, with no weighting based on the size of the animal groups). Contact transmission groups were not included
in the summary.
(c): Min = ﬁrst day (in dpi) in which clinical signs were observed in each whole animal group reported; Max = last day (in dpi) in
which clinical signs were observed in each whole animal group reported. Min and Max were recorded individually for each
animal group, and median (min-max) for each of those values were calculated from all group data (each group representing
one observation, with no weighting based on the size of the animal groups). Contact transmission groups were not included
in the summary.
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Appendix B – List of wild and domestic WNV reservoir/sentinel animal
species
Table B.1: List of wild and domestic WNV reservoir/sentinel animal species
Family Reservoir Sentinel Notes
Turdidae ND Y Intense viraemia and clinical signs developed by infected birds
Corvidae Potential Y Intense viraemia and clinical signs developed by the infected birds
with high mortality
Passeridae Y Y Intense and long viraemia and clinical signs developed by infected
birds
Anatidae – Y Intense viraemia and clinical signs developed by infected birds
Columbidae Y – Common ground-dove (Columbina passerina): WNV detection in
spleen and kidney and lung at > 6 weeks p.i
Fringillidae Y – Persistent infection in house ﬁnches (Haemorhous mexicanus)
Falconidae – Y Intense viraemia and clinical signs developed by infected birds
Phasianidae – Y Viraemia short and scarce, asymptomatic infection, detectable
serological response
Laridae – Y Intense viraemia and clinical signs developed by infected birds
Strigidae Y Intense viraemia and clinical signs developed by infected birds
Equidae – Y Viraemia short and scarce, development of clinical symptoms,
detectable serological response
Canidae – Potential Viraemia short and scarce, rare development of clinical symptoms,
detectable serological response. Potential use as sentinel in urban
areas
Felidae – Potential Viraemia short and scarce, rare development of clinical symptoms,
detectable serological response. Potential use as sentinel in urban
areas
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Appendix C – WNV morbidity and mortality rates in horses
Table C.1: WNV morbidity and mortality rates in horses (2010–2016 EU outbreaks)
Outbreaks in equids
Country Year
No
outbreaks
No
outbreaks
with clinical
symptoms
No
horses
present
No
total
cases
No
horses with
symptoms
Died/
culled
Prevalence of
infection
Case-
morbidity
rate
Case-
fatality rate
Italy 2008 273 18 1,941 563 32 5 29% 2% 1%
2009 137 32 1,398 223 37 9 16% 3% 24%
2010 67 11 415 128 11 5 31% 3% 45%
2011 91 41 881 197 58 14 22% 7% 24%
2012 30 13 313 63 15 3 20% 24% 20%
2013 35 11 308 50 12 1 16% 24% 8%
2014 17 6 257 27 6 2 11% 22% 33%
2015 26 6 302 30 6 5 10% 20% 17%
2016* 33 13 310 37 13 4 7% 35% 11%
Portugal 2016 1 1 2 1 1 0 50% 50% 0%
2015 3 3 82 4 4 0 5% 5% 0%
2010 2 2 71 2 2 1 3% 3% 1%
Spain 2011 5 Unknown 44 11 Unknown 1 25% Unknown 9%
2010 31 2 845 39 2 2 4% 0% 5%
France 2015 35 26 262 49 34 5 19% 13% 0–5,
26%
2006 4 1 63 4 1 1 6% 2% 25%
Croatia 2014 1 0 2 1 0 0 50% 0% 0%
2012 11 0 87 12 0 0 14% 0% 0%
Greece 2014 4 0 51 4 0 0 8% 0% 0%
2013 10 2 559 15 2 1 3% 0% 7%
2012 14 3 100 15 3 0 15% 3% 0%
2011 17 0 374 23 0 1** 6% 0% 0%
2010 27 3 559 30 3 3 5% 1% 10%
Romania 2010 3 Unknown 9 6 Unknown 0 67% Unknown Unknown
Former
Yugoslav
Republic of
Macedonia
2011 4 0 51 10 0 0 20% 0% 0%
Bulgaria 2010 2 0 118 8 0 0 7% 0% 0%
*: 2016 Italian data: updated to 14 October 2016.
**: Death may have been the result of conditions other than West Nile virus infection (possible snake bite reported).
Source: Italian National information system and (OIE, online).
www.efsa.europa.eu/efsajournal 51 EFSA Journal 2017;15(8):4955
AHL assessment on West Nile fever
